A Study of BEBT-209 in Combination With Chemotherapy for the Treatment of Advanced Triple-Negative Breast Cancer

This study tests a new drug called BEBT-209 combined with chemotherapy (carboplatin and gemcitabine) in women with triple-negative breast cancer — a type that lacks hormone receptors and HER2 — that has come back or spread after 1–2 prior treatments. **You may be eligible if...** - You are a woman aged 18 or older - You have been confirmed to have triple-negative (HR-negative, HER2-negative) breast cancer that is locally advanced or metastatic - Your cancer has received 1–2 prior lines of treatment - You have at least one measurable tumor on a scan - You are physically functional (ECOG 0–1) - Your blood counts and organ function are in an acceptable range **You may NOT be eligible if...** - You have previously been treated with gemcitabine - You have brain metastases requiring immediate treatment - You have had a bone marrow or stem cell transplant - You have a history of serious heart problems - You are pregnant or breastfeeding - You have active hepatitis B, hepatitis C, or HIV Talk to your doctor to see if this trial is right for you.